Abstract
Background: Selective agents able to locate and identify unique targets represent a crucial aspect of modern pharmacology. The exclusive location of Sodium-Glucose co-Transporter-2 (SGLUT2) on kidneys prompt companies to develop SGLT2 inhibitors that today are the latest class of drugs for diabetes treatment. In particular, canagliflozin blocks the re-absorption of glucose in the kidney lowering blood glucose levels by increasing glucose excretion.
Case Description: We report a 61-year old woman who developed an intense and severe pruritus during the treatment with canagliflozin. Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce pruritus. The discontinuation of canagliflozin and the treatment with pioglitazone/metformin fixed combination induced a remission of pruritus.
Conclusion: This case emphasizes the need to consider pruritus as a differential diagnosis during the treatment with canagliflozin.
Keywords: Pruritus, canagliflozin, adverse drug reaction, SGLT2, pharmacology, sodium-glucose.
Graphical Abstract
Current Drug Safety
Title:Generalized Intense Pruritus During Canagliflozin Treatment: Is it an Adverse Drug Reaction?
Volume: 13 Issue: 1
Author(s): Piero Vasapollo, Erika Cione, Filippo Luciani and Luca Gallelli*
Affiliation:
- Department of Health Science, University of Catanzaro and Operative Unit of Clinical Pharmacology and Pharmacovigilance, Mater Domini Hospital, Catanzaro,Italy
Keywords: Pruritus, canagliflozin, adverse drug reaction, SGLT2, pharmacology, sodium-glucose.
Abstract: Background: Selective agents able to locate and identify unique targets represent a crucial aspect of modern pharmacology. The exclusive location of Sodium-Glucose co-Transporter-2 (SGLUT2) on kidneys prompt companies to develop SGLT2 inhibitors that today are the latest class of drugs for diabetes treatment. In particular, canagliflozin blocks the re-absorption of glucose in the kidney lowering blood glucose levels by increasing glucose excretion.
Case Description: We report a 61-year old woman who developed an intense and severe pruritus during the treatment with canagliflozin. Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce pruritus. The discontinuation of canagliflozin and the treatment with pioglitazone/metformin fixed combination induced a remission of pruritus.
Conclusion: This case emphasizes the need to consider pruritus as a differential diagnosis during the treatment with canagliflozin.
Export Options
About this article
Cite this article as:
Vasapollo Piero, Cione Erika, Luciani Filippo and Gallelli Luca*, Generalized Intense Pruritus During Canagliflozin Treatment: Is it an Adverse Drug Reaction?, Current Drug Safety 2018; 13 (1) . https://dx.doi.org/10.2174/1574886311666160405110515
DOI https://dx.doi.org/10.2174/1574886311666160405110515 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Wnt1 Inducible Signaling Pathway Protein 1 (WISP1) Targets PRAS40 to Govern β-Amyloid Apoptotic Injury of Microglia
Current Neurovascular Research Perinatal and Neonatal Outcomes of Lithium-Treated and Untreated Bipolar Women During Pregnancy: A Review of Present Literature
Current Psychopharmacology Modified-Release Solid Formulations for Colonic Delivery
Recent Patents on Drug Delivery & Formulation Subject Index To Volume 7
Current Protein & Peptide Science Systemic Drug Delivery Systems for Bone Tissue Regeneration– A Mini Review
Current Pharmaceutical Design Recent Updates on Glucokinase Activators and Glucokinase Regulatory Protein Disrupters for the Treatment of Type 2 Diabetes Mellitus
Current Diabetes Reviews The Role of Chromogranins and Other Statins in Homeostasis: An Explanation of the Precise Regulation of Glucose and Ionised Calcium in the Blood; An Overview
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Perspectives of Engineered Marine Derived Polymers for Biomedical Nanoparticles
Current Pharmaceutical Design Resveratrol and Stroke: from Chemistry to Medicine
Current Neurovascular Research Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Insights into the Relationship Between Hypertension and Albuminuria
Current Hypertension Reviews Noncoding RNAs and Intracerebral Hemorrhage
CNS & Neurological Disorders - Drug Targets Involvement of L-Carnitine in Cellular Metabolism: Beyond Acyl-CoA Transport
Mini-Reviews in Medicinal Chemistry The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors
Current Drug Metabolism Genetic and Non-genetic Determinants of Cardiovascular Disease in South Asians
Current Diabetes Reviews Medication Adherence of Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Considering the Psychosocial Factors, Health Literacy and Current Life Concerns of Patients
Current Rheumatology Reviews Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Current Genomics Rediscovery of Caffeine: An Excellent Drug for Improving Patient Outcomes while Fighting WARS
Current Medicinal Chemistry Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Metabolic Regulation and Behavior: How Hunger Produces Arousal - An Insect Study
Endocrine, Metabolic & Immune Disorders - Drug Targets